De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor

Journal of Medicinal Chemistry

Volumn 46, Issue 8, 2003, Pages 1408-1418

  Schmidt, Jonathan M ^a   Mercure, Julie ^a,b   Tremblay, Gilles B ^a   Pagé, Martine ^a   Kalbakji, Aida ^a   Feher, Miklos ^a   Dunn Dufault, Robert ^a   Peter, Markus G ^a   Redden, Peter R ^a  

^a Signalgene Inc Canada   (Canada)

^b SYNX Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 HYDROXY 5 METHYL 10 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PHENANTHREN 2 YL]ETHANONE; 1 [7 HYDROXY 5 METHYL 10 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PHENANTHREN 7 YL] 2 METHYLPROPAN 1 ONE; 7 (1 HYDROXYETHYL) 4 METHYL 9 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PHENANTHREN 2 OL; 7 (1,2 DIMETHYLPROPENYL) 4 METHYL 9 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PHENANTHREN 2 OL; 7 ISOPRENYL 4 METHYL 9 [4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PHENANTHREN 2 OL; 9,10 DIHYDROPHENANTHRENE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; LY 335124; LY 357489; PHENANTHRENE DERIVATIVE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; STRUCTURE ANALYSIS;

ANIMALS; BINDING, COMPETITIVE; CELL DIVISION; CELL LINE; CERCOPITHECUS AETHIOPS; COMPUTER SIMULATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; HUMANS; LIGANDS; MODELS, MOLECULAR; PHENANTHRENES; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037431396     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020536q     Document Type: Article

References (39)

1. Carson-Jurica, M. A.; Schrader, W. T.; O'Malley, B. W. Steroid Receptor Family: Structure and Functions. Endocrinol. Rev. 1990, 11, 201-220.
2. Jordan, V. C. Studies on the Estrogen Receptor in Breast Cancer - 20 Years as a Target for the Treatment and Prevention of Breast Cancer. Breast Cancer Res. Treat. 1995, 36, 267-285.
3. Gradishar, W. J.; Jordan, V. C. Clinical Potential of New Antiestrogens. J. Clin. Oncol. 1997, 15, 840-852.
4. Jordan, V. C. Molecular Mechanisms of Antiestrogen Action in Breast Cancer. Breast Cancer Res. Treat. 1994, 31, 41-52.
5. Mitlak, B. H.; Cohen, F. J. In Search of Optimal Long-Term Female Hormone Replacement: The Potential of Selective Estrogen Receptor Modulators. Horm. Res. 1997, 48, 155-163.
6. Smith, C. L.; O'Malley, B. W. Evolving Concepts of Selective Estrogen Receptor Action: From Basic Science to Clinical Applications. Trends Endocrinol. Metab. 1999, 10, 299-300.
7. McDonnell, D. P. The Molecular Pharmacology of SERMs. Trends Endocrinol. Metab. 1999, 10, 301-311.
8. MacGregor, J.; Jordan, V. G. Basic Guide to the Mechanism of Antiestrogen Action. Pharmacol. Rev. 1998, 50, 151-196.
9. Mosselman, S.; Polman, P.; Dijkema, R. ER beta: Identification and Characterization of a Novel Human Estrogen Receptor. FEBS Lett. 1996, 392, 49-53.
10. Hall, J. M.; McDonnell, D. P. The Estrogen Receptor beta-Isoform (ERbeta) of the Human Estrogen Receptor Modulates ERalpha Transcriptional Activity and is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens. Endocrinology 1999, 140, 5566-5578.
11. Pennisi, E. Differing Roles Found for Estrogen's Two Receptors. Mol. Endocrinol. 1997, 277, 1439-1510.
12. Mitlak, B. H.; Cohen, F. J. Selective Estrogen Receptor Modulators: A Look Ahead. Drugs 1999, 57, 653-663.
13. Grese, T. A.; Pennington, J. P.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Blasebrook, A. L.; Bryant, H. U. Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators. J. Med. Chem. 1998, 41, 1272-1283.
14. Black, L. J.; Jones, C. D.; Falcone, J. F. Antagonism of Estrogen Action with a New Benzothiophene Derived Antiestrogen. Life Sci. 1983, 28, 1031-1036.
15. Foster, A. B.; Jarman, M.; Leung, O. T.; McCague, R.; Leclercq, G.; Devleeschouwer, N. Hydroxy Derivatives of Tamoxifen. J. Med. Chem. 1985, 28, 1491-1497.
16. Chander, S. K.; McCague, R.; Luqmani, Y.; Newton, C.; Dowsett, M.; Jarman, M.; Coombes, R. C. Pyrrolidino-4-Iodotamoxifen and 4-Iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer. Cancer Res. 1991, 51, 5851-5858.
17. Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.; Kharode, Y. P.; Marzolf, J. T.; Moran, R. A.; Henderson, R. A.; Bender, R. H. W.; Unwalla, R. J.; Greenberger, L. M.; Yaardley, J. P.; Abou-Gharbia, M. A.; Lyttle, C. R.; Komm, B. S. Design, synthesis and Preclinical Characterization of Novel, Highly Selective Indole Estrogens. J. Med. Chem. 2001 44, 1654-1657.
18. Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche, D.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Leblanc, G.; Martel, C.; Simard, J.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2- (1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2, 2-dimethylpropanoate(EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen. J. Med. Chem. 1997, 40, 2117-2122.
19. Labrie, F.; Labrie, C.; Belanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Merand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpenet, G.; Tremblay, A.; Tremblay, G.; Cusan, L.; Veilleux, R. EM-652 (SCH 57068), a Third Generation SERM Acting as Pure Antiestrogen in the Mammary Gland and Endometrium. J. Steroid Biochem. Mol. Biol. 1999, 69, 51-84.
20. Schmidt, J. M., University of Guelph, US Patent 5699268, 1995.
21. Wiese, T. E.; Polin, L. A.; Palomino, E. and Brooks, S. K. Induction of the Estrogen Specific Response of MCF-7 Cells by Selected Analogues of Estradiol-17β: A 3D QSAR Study. J. Med. Chem. 1997, 40, 3659-3669.
22. Kvita, V.; Sauter, H. The Synthesis of Some 2H-Pyran-2-one Derivatives. Helv. Chim. Acta 1990, 73, 883.
23. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucl. Acid Res. 2000, 28, 235-242.
24. Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W., III; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. Dee; Cole, H. W.; Magee, D. E.; Phillips, D. Lynn; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure - Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene. J. Med. Chem. 1997, 40, 146-167.
25. Sata, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis. J. Med. Chem. 1999, 42, 1-24.
26. Grese, T. A.; Adrian, M. Dee; Phillips, D. Lynn; Shelter, P. K.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Photochemical Synthesis of N-Arylbenzophenanthridine Selective Estrogen Modulators (SERMs). J. Med. Chem. 2001, 44, 2857-2860.
27. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynanmics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
28. Qiu, D.; Shenkin, S.; Hollinger, F. P.; Still, W. C. The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii. J. Phys. Chem. A 1997, 101, 3005-3014.
29. Schaefer, M.; Karplus, M. A. Comprehensive Analytical Treatment of Continuum Electrostatics. J. Phys. Chem. 1996, 100, 1578-1599.
30. Molecular Operating Environment, Version 2001.01. Chemical Computing Group Inc., Montreal, Quebec, Canada. (http://www.chemcomp.com).
31. Hart, T. N.; Read, R. J. A Multiple-Start Monte Carlo Docking Method. PROTEINS: Struct. Func. Genet. 1992, 13, 206-222.
32. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olsen, A. J. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Design. 1996, 10, 293-304.
33. Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M. D.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, L. J.; deSolms, S. J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, M.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L. and Zugay, J. A. A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site. J. Med. Chem. 1995, 38, 305-317.
34. Shen, J.; Pearlstein, R. A.; Vaz, R. J.; Kominos, D.; Effland, R. C. The Use of Interaction Energy and Solvation Entropy to Rank Order Docked Ligand-Protein Complexes for Lead Optimization: Application to Thermolysin Inhibitors. Med. Chem. Res. 1999, 9, 501-512.
35. Metropolis, N.; Rosenbluth, A. W.; Rosenbluth, M. N.; Teller, A. H. Equation of State Calculations by Fast Computing Machines. J. Chem. Phys. 1953, 21, 1087-1092.
36. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Research Paper-Novel Structural Templates for Estrogen-Receptor Ligands and Prospects for Combinatorial Synthesis of Estrogens. Chem. Biol. 1999, 6, 205-219.
37. Halgren, T. A. The Merck Molecular Force Field. I. Basis, Form, Scope, Parametrization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
38. Ferguson, D. M.; Raber, D. J. A New Approach to Probing Conformational Space with Molecular Mechanics: Random Incremental Pulse Search. J. Am. Chem. Soc. 1989, 111, 4371-4378.
39. Tremblay, A.; Tremblay, G. B.; Labrie, C.; Labrie, F.; and Giguere, V. EM-800, a Novel Antiestrogen, Acts as a Pure Antagonist of the Transcriptional Functions of Estrogen Receptors α and β. Endocrinology 1998, 139, 111-118.